Complexed prostate-specific antigen for the detection of prostate cancer

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4181-4185

  Filella, Xavier ^a   Truan, David ^a   Alcover, Joan ^a   Gutierrez, Rafael ^a   Molina, Rafael ^a   Coca, Francisca ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

cPSA; Free PSA; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; ENZYME IMMUNOASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; ANALYTICAL EQUIPMENT; BLOOD; PROSPECTIVE STUDY; PROSTATE TUMOR; ROC CURVE;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; ROC CURVE;

EID: 14944377110     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Allard WJ, Zhou Z and Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 44: 1216-1223, 1998.
2. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K and Lovgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
3. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K and Alfthan O: A complex between prostate-specific antigen and alfa-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 57: 222-226, 1991.
4. Leinonen J, Lövgren T, Vornanen T and Stenman UH: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1-antichymotrypsin. Clin Chem 39: 2098-2103, 1993.
5. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH and Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 48: 55-61, 1996.
6. Filella X, Alcover J, Molina R, Rodríguez A and Carretero P, Ballesta AM: Free and total PSA in the diagnosis of prostate cancer. Tumor Biology 18: 332-340, 1997.
7. Woodrum DL, Brawer MK, Partin AW, Catalona WJ and Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 759: 5-12, 1998.
8. 1- antichymotrypsin in blood samples. Urology 48: 81-87, 1996.
9. Arcangeli CG, Smith DS, Ratliff TL and Catalona WJ: Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 158: 2182-2187, 1997.
10. Brawer MK, Meyer GE, Letran JL, Bankson ER, Morris DL, Yeung KK and Allard WJ: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52: 372-378, 1998.
11. Ellison L, Cheli CD, Bright S, Veltri RW and Partin AW: Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology 60(suppl 4A): 42-46, 2002.
12. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A and Marbergeret M: Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 60(4 Suppl. 1): 4-9, 2002.
13. Filella X, Alcover J and Molina R, Corral JM, Carretero P and Ballesta AM: Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. The Prostate 42: 181-185, 2000.
14. Filella X, Alcover J, Corral JM, Molina R, Beardo P and Ballesta AM: Free and complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer. Anticancer Res 21: 3717-3720, 2001.
15. Ambruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39: 181-195, 1993.
16. Lein M, Jung K, Hammerer P, Graefen M, Semjonov A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schorr D and Loening SA: A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific-antigen in prostate cancer diagnosis. Prostate 47: 77-84, 2001.
17. Jung K, Brux B, Knäbich A, Lein M, Sinha P, Schnorr D and Loening SA: A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus a1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clin Chem 45: 422-424, 1999.
18. Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, Sinha P, Winkelmann B, Schnorr D and Loening S: Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 39: 57-64, 2001.
19. Lein M, Kwiatkowski M, Semjonov A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA and Jung K: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 770: 1175-1179, 2003.
20. Wu JT and Liu GH: Advantages of replacing the total PSA assay with the assay for PSA-alpha-1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 12: 32-40, 1998.